|
"avallone a"的相关文件
显示项目 1-6 / 6 (共1页)
1
每页显示[10|25|50]项目
| 國家衛生研究院 |
2024-08 |
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study
|
Oh, DY;He, AR;Bouattour, M;Okusaka, T;Qin, S;Chen, LT;Kitano, M;Lee, CK;Kim, JW;Chen, MH;Suksombooncharoen, T;Ikeda, M;Lee, MA;Chen, JS;Potemski, P;Burris, HA, 3rd;Ostwal, V;Tanasanvimon, S;Morizane, C;Zaucha, RE;McNamara, MG;Avallone, A;Cundom, JE;Breder, V;Tan, B;Shimizu, S;Tougeron, D;Evesque, L;Petrova, M;Zhen, DB;Gillmore, R;Gupta, VG;Dayyani, F;Park, JO;Buchschacher, GL, Jr.;Rey, F;Kim, H;Wang, J;Morgan, C;Rokutanda, N;Żotkiewicz, M;Vogel, A;Valle, JW |
| 國家衛生研究院 |
2023-09-25 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
|
Oh, DY;He, AR;Qin, SK;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, H;Bouattour, M;Tanasanvimon, S;McNamara, MG;Zaucha, R;Avallone, A;Tan, BJM;Cundom, J;Lee, CK;Takahashi, H;Ikeda, M;Chen, JS;Wang, JL;Makowsky, M;Rokutanda, N;Zotkiewicz, M;Kurland, JF;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2023-03-31 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462
|
Oh, D;He, AR;Qin, S;Chen, L;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasa, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Żotkiewicz, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2022-11 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Lee, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Zotkiewicz, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2022-09 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Watras, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2022-02-01 |
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, R;Avallone, A;Cundom, J;Rokutanda, N;Xiong, J;Cohen, G;Valle, JW |
显示项目 1-6 / 6 (共1页)
1
每页显示[10|25|50]项目
|
